About The Study: The findings of this study of 68,000 patients who received a diagnosis of COVID-19 and who were at high risk of progressing to severe COVID-19 suggest that the use of either nirmatrelvir (Paxlovid) or molnupiravir (Lagevrio) is associated with reductions in mortality and hospitalization in patients infected with Omicron, regardless of age, race and ethnicity, virus strain, vaccination status, previous infection status, or coexisting conditions. Both drugs can, therefore, be used to treat non-hospitalized patients who are at high risk of progressing to severe COVID-19.
Authors: Dan-Yu Lin, Ph.D., of the University of North Carolina in Chapel Hill, and Xiaofeng Wang, Ph.D., of the Cleveland Clinic, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.35077)
